tetano
Editor, Senior Moderator
J Infect Dis. 2015 Sep 15. pii: jiv453. [Epub ahead of print]
[h=1]INSIGHT FLU005: An Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study.[/h] Davey RT Jr, Markowitz N, Beigel J, Wentworth D, Babiker A, Rehman T, Dewar R, Metcalf J, Uyeki TM, Finley EB, Standridge B, Riska P, Lane HC, Gordin F, Neaton JD; INSIGHT FLU005 IVIG Pilot Study Group.
[h=3]Collaborators (32)[/h]
[h=3]Abstract[/h] Hemagglutination inhibition (HAI) antibody responses to anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one influenza patients (2013-2014) were randomized to 0.25 G/kg of hIVIG (n=16) or placebo (n=15). For hIVIG recipients the ratio of geometric mean titers (1-hour post-infusion/pre-infusion) was 4.00 (95% CI=2.61-6.13) for influenza A(H1N1)pdm09 and 1.76 (95% CI=1.33-2.32) for A(H3N2) and influenza B. Among patients with A(H1N1)pdm09 virus, ratios for hIVIG (n=9) versus placebo (n=8), were higher 1-hour post-infusion [3.9 (95% CI: 2.3-6.7)] and sustained through day 3 [2.0 (95% CI: 1.0-4.0)]. hIVIG administration significantly increases HAI titer levels among influenza patients supporting a clinical outcomes study.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 26374911 [PubMed - as supplied by publisher]
[h=1]INSIGHT FLU005: An Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study.[/h] Davey RT Jr, Markowitz N, Beigel J, Wentworth D, Babiker A, Rehman T, Dewar R, Metcalf J, Uyeki TM, Finley EB, Standridge B, Riska P, Lane HC, Gordin F, Neaton JD; INSIGHT FLU005 IVIG Pilot Study Group.
[h=3]Collaborators (32)[/h]
[h=3]Abstract[/h] Hemagglutination inhibition (HAI) antibody responses to anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one influenza patients (2013-2014) were randomized to 0.25 G/kg of hIVIG (n=16) or placebo (n=15). For hIVIG recipients the ratio of geometric mean titers (1-hour post-infusion/pre-infusion) was 4.00 (95% CI=2.61-6.13) for influenza A(H1N1)pdm09 and 1.76 (95% CI=1.33-2.32) for A(H3N2) and influenza B. Among patients with A(H1N1)pdm09 virus, ratios for hIVIG (n=9) versus placebo (n=8), were higher 1-hour post-infusion [3.9 (95% CI: 2.3-6.7)] and sustained through day 3 [2.0 (95% CI: 1.0-4.0)]. hIVIG administration significantly increases HAI titer levels among influenza patients supporting a clinical outcomes study.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 26374911 [PubMed - as supplied by publisher]